Advanced

Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality.

Eberhard, Jakob LU ; Ståhl, Olof LU ; Cohn-Cedermark, Gabriella; Cavallin-Ståhl, Eva LU ; Giwercman, Yvonne LU ; Rastkhani, Hamideh LU ; Rylander, Lars LU ; Eberhard-Gran, Malin; Kvist, Ulrik and Giwercman, Aleksander LU (2010) In Journal of Affective Disorders 122. p.260-266
Abstract
PURPOSE: It has been documented that testicular germ cell cancer (TGCC) patients may be at increased risk of developing emotional distress (EMD). Hence, the aim of the present study was to investigate whether EMD is related to the presence of hypogonadism, androgen receptor (AR) polymorphism and/or treatment intensity. PATIENTS AND METHODS: Three to five years after treatment, testosterone and luteinizing hormone (LH) levels were measured in 165 TGCC patients. These patients also completed a questionnaire concerning mental health. EMD was measured by the Hospital Anxiety and Depression Scale (HADS). The androgen receptor (AR) gene has two polymorphic regions in exon I; glutamine encoding CAG and glycine encoding GGN repeats. Association... (More)
PURPOSE: It has been documented that testicular germ cell cancer (TGCC) patients may be at increased risk of developing emotional distress (EMD). Hence, the aim of the present study was to investigate whether EMD is related to the presence of hypogonadism, androgen receptor (AR) polymorphism and/or treatment intensity. PATIENTS AND METHODS: Three to five years after treatment, testosterone and luteinizing hormone (LH) levels were measured in 165 TGCC patients. These patients also completed a questionnaire concerning mental health. EMD was measured by the Hospital Anxiety and Depression Scale (HADS). The androgen receptor (AR) gene has two polymorphic regions in exon I; glutamine encoding CAG and glycine encoding GGN repeats. Association between emotional disorders and AR polymorphisms as well as type of treatment was assessed. RESULTS: Neither anxiety (OR 1.0; 95% CI 0.40-2.4) nor depression (OR 1.1; 95% CI 0.20-6.4) were overrepresented in biochemically hypogonadal TGCC patients and no association between AR polymorphisms and EMD was found. Patients treated with >/=5 cycles of cisplatinum based chemotherapy due to refractory or relapsed disease were more prone to experiencing symptoms of anxiety (p=0.006), but not depression (p=0.38). CONCLUSIONS: Biochemical hypogonadism and AR polymorphism do not seem to be risk factors for EMD in TGCC patients. Patients with refractory or relapsed disease receiving >/=5 cycles of cisplatinum based chemotherapy may, to a higher degree than patients receiving less intense therapy, suffer from anxiety. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Affective Disorders
volume
122
pages
260 - 266
publisher
Elsevier
external identifiers
  • wos:000277099300011
  • pmid:19656574
  • scopus:77949656645
ISSN
1573-2517
DOI
10.1016/j.jad.2009.06.035
language
English
LU publication?
yes
id
aa5fcfed-a20e-4df0-92ed-8a504a8b5d6f (old id 1470002)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19656574?dopt=Abstract
date added to LUP
2009-09-08 09:38:13
date last changed
2018-06-03 04:32:55
@article{aa5fcfed-a20e-4df0-92ed-8a504a8b5d6f,
  abstract     = {PURPOSE: It has been documented that testicular germ cell cancer (TGCC) patients may be at increased risk of developing emotional distress (EMD). Hence, the aim of the present study was to investigate whether EMD is related to the presence of hypogonadism, androgen receptor (AR) polymorphism and/or treatment intensity. PATIENTS AND METHODS: Three to five years after treatment, testosterone and luteinizing hormone (LH) levels were measured in 165 TGCC patients. These patients also completed a questionnaire concerning mental health. EMD was measured by the Hospital Anxiety and Depression Scale (HADS). The androgen receptor (AR) gene has two polymorphic regions in exon I; glutamine encoding CAG and glycine encoding GGN repeats. Association between emotional disorders and AR polymorphisms as well as type of treatment was assessed. RESULTS: Neither anxiety (OR 1.0; 95% CI 0.40-2.4) nor depression (OR 1.1; 95% CI 0.20-6.4) were overrepresented in biochemically hypogonadal TGCC patients and no association between AR polymorphisms and EMD was found. Patients treated with >/=5 cycles of cisplatinum based chemotherapy due to refractory or relapsed disease were more prone to experiencing symptoms of anxiety (p=0.006), but not depression (p=0.38). CONCLUSIONS: Biochemical hypogonadism and AR polymorphism do not seem to be risk factors for EMD in TGCC patients. Patients with refractory or relapsed disease receiving >/=5 cycles of cisplatinum based chemotherapy may, to a higher degree than patients receiving less intense therapy, suffer from anxiety.},
  author       = {Eberhard, Jakob and Ståhl, Olof and Cohn-Cedermark, Gabriella and Cavallin-Ståhl, Eva and Giwercman, Yvonne and Rastkhani, Hamideh and Rylander, Lars and Eberhard-Gran, Malin and Kvist, Ulrik and Giwercman, Aleksander},
  issn         = {1573-2517},
  language     = {eng},
  pages        = {260--266},
  publisher    = {Elsevier},
  series       = {Journal of Affective Disorders},
  title        = {Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality.},
  url          = {http://dx.doi.org/10.1016/j.jad.2009.06.035},
  volume       = {122},
  year         = {2010},
}